Application of immunotherapy, especially programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies, to a variety of solid tumors (including HCC) represents a major breakthrough in cancer treatment 8, 9. Here, CD274 is linked to hepatocellular carcinoma.